Hiking effects on quality of life during Chemotherapy treatment of Breast Cancer

Not Applicable

• Conditions: Myelosuppression, malaise, muscle fatigue, women.; R76.9; M01.975

• Registration Number: RBR-4bxrfy
• Lead Sponsor: Instituto Radium de Campinas Ltda (filial São João da Boa Vista)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-04
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women on adjuvant chemotherapy; who were in the second, third or fourth cycle of chemotherapy; and who performed the cycle of Doxorubicin and Cyclophosphamide use.

Exclusion Criteria

Women who have had radiation therapy or hormone therapy; who performed the cycle of use Placlitaxel or FEC (Fluorouracil, Epirubicin and Cyclophosphamide); who had high cardiac risk on the echocardiogram; above 75 years of age; unable to respond to questionnaires; with distant metastasis; and unable to walk.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increase in overall quality of life, determined through the FACT-B total questionnaire, at the beginning of the study and at the end of the study.;The total sum of the indices of each group, obtained at the end of the intervention or control, showed an increase in the general quality of life of the experimental group, resulting in the comparative p = 0.042.

Secondary Outcome Measures

Name	Time	Method
Positive effects for the immune system, evaluated through a complete blood count, at the beginning and at the end of the study.;Increase in the value of monocytes in the experimental group, determined in a hemogram at the beginning and at the end of the study, with a mean change from 365.3 / mm3 to 455.2 / mm3 and a decrease in the control group, with a mean variation of 232, 2 / mm 3 to 211.2 / mm 3; And low basophil value reduction in the control group, with a mean variation from 5.65 / mm 3 to 5.17 / mm 3, while in the experimental group the variation was from 8.83 / mm 3 to 5.33 / mm 3.